Amarin Corporation(AMRN) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - For the full year 2025, total net revenue was $49.2 million, down from $62.3 million in the previous year’s fourth quarter, reflecting a 21% decline [21] - U.S. sales declined by 7% due to a decrease in net selling price, driven by proactive pricing adjustments [21] - Total operating expenses decreased by 31%, or $13.5 million, with cost of goods sold declining by 63% [23] - The operating loss in the fourth quarter narrowed to $2.3 million from an operating loss of $16 million in the previous year’s fourth quarter [25] - The company ended 2025 with $303 million in cash and investments, no debt, and working capital of $455 million [25] Business Line Data and Key Metrics Changes - Product revenue for Europe was $2.3 million, including $900,000 in supply shipments to Recordati, significantly lower than the $4 million of direct sales in the fourth quarter of 2024 [21][22] - Rest of World revenues were $3.1 million, down from $11.9 million in the previous year’s fourth quarter, impacted by $7.8 million in stocking orders in the last quarter of 2024 [22] Market Data and Key Metrics Changes - VASCEPA maintained clear market leadership in the U.S. across all available icosapent ethyl products, both branded and generic, five years after the introduction of the first generic product [8] - The partnership with Recordati aims to capitalize on the growing awareness of lipid management protocols in Europe, where cardiovascular disease is a leading cause of death [9] Company Strategy and Development Direction - The company established a long-term partnership with Recordati to commercialize VAZKEPA across Europe, aiming to enhance the global market for its franchise [4] - The strategy includes a focus on operational efficiencies and a global restructuring plan expected to yield approximately $70 million in annualized savings by mid-2026 [5][26] - The company is committed to enhancing long-term shareholder value by addressing cardiovascular disease as a leading cause of death [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the durability of the VASCEPA franchise and its global growth potential, supported by extensive scientific evidence [7] - The company anticipates 2026 to be a pivotal year, focusing on defending its U.S. franchise and expanding its global presence through the international partnership model [19][25] - Management highlighted the importance of maintaining exclusivity in the U.S. market and expressed confidence in sustaining it through 2026 [38] Other Important Information - The company reported generating positive cash flow from operations of $7 million in 2025, earlier than anticipated [25] - The partnership model will result in revenue variability quarter-to-quarter, influenced by market demand and launch timing [23] Q&A Session Summary Question: Could you provide more color on the volume versus price dynamics in 4Q? - Management noted that volume and price remained consistent compared to Q3, with typical volume declines expected in Q1 [31][32] Question: How confident are you in sustaining exclusivity with your existing exclusive formulary in 2026? - Management expressed confidence in maintaining exclusivity through 2026, despite the dynamic nature of the market [38]